Engineered Yeast Could Reduce Drug Shortages
Brewer’s yeast engineered with synthetic biology to produce drugs or raw materials could transform pharmaceutical supply chains.
Forbes’ Top Ten Women Founders in the Synthetic Biology Industry
Our co-founder and CEO, Christina Smolke, was named to Forbes’ list of top ten women founders taking the synthetic biology world by storm. From her groundbreaking work at Stanford to the impressive team she has built at Antheia, Christina has been a pioneer in the synbio space and we are thrilled to see her recognized alongside an esteemed group of individuals who are unlo
Antheia’s 2022 in Review: A Year of Value
This year has been ripe with growth, major achievements, and opportunities to showcase who and what make Antheia the visionary business it is. Nearly eight years ago, we co-founded Antheia…
Demystifying Synthetic Biology Part V: The Product is Key in Downstream Processing
Upstream bioprocessing – better known in biomanufacturing as fermentation – is directly followed by downstream bioprocessing (DSP). Just as fermentation is all about maximizing the production of a target compound, DSP focuses
Dr. Christina Smolke of Antheia On The 5 Leadership Lessons She Learned From Her Experience
As a part of my series about “Lessons From Inspirational Women in STEM and Tech”, I had the pleasure of interviewing Christina Smolke…
Making Drugs From Yeast
Antheia CEO Christina Smolke brews up new pharmaceuticals…
Join the Movement to Build a Century-Defining Technology
Synthetic biology isn’t a household name – yet. But it will be soon, because it’s a thriving, innovative field that’s solving some of humanity’s greatest and most pressing challenges…
On Heels of $17 Billion SPAC Deal, Ginkgo Inks Collab with Synthetic Biology Firm
California synthetic biology firm Antheia has joined forces with Boston-based biotech company Ginkgo Bioworks to strengthen its efforts to develop and produce essential medicines to treat a wide range of diseases…
Out to revamp plant-based drug manufacturing, Antheia locks in partnership with synthetic biology…
With supply chain shortages at the forefront of nearly every business in the world right now, whether it be chicken wings or CAR-T cell therapy, synthetic biology upstart Antheia…
Antheia Raises $73M in Series B
Antheia, a Menlo Park CA-based synthetic biology company, raised $73M in Series B funding. The round was led by Viking Global Investors with participation from Sherpalo Ventures and Hillspire…